口服钙补充剂与系列冠状动脉钙化的关联:血管内超声研究
该研究是对9项前瞻性随机试验的事后患者水平分析,采用系列冠状动脉血管内超声比较服用钙补充剂者(n=447)与未服用者(n=4,700)在18至24个月内的斑块体积百分比和钙化指数变化。校正多种协变量后,两组斑块体积百分比年化变化无显著差异,但钙补充剂独立与钙化指数年化增加相关(OR 1.15,95%CI 1.05–1.26,P=0.004)。作者认为口服钙补充剂可能在不依赖斑块体积变化的情况下增加冠状动脉钙沉积,其对斑块稳定性和心血管结局的影响需进一步研究。
要点
- 口服钙补充剂独立与冠状动脉钙化指数年化增加相关(OR 1.15,95%CI 1.05–1.26,P=0.004)。
- 钙补充剂组与未服用组斑块体积百分比年化变化无显著组间差异(P=0.092)。
- 钙补充剂可能在不改变斑块体积的情况下增加冠状动脉钙沉积。
诊断标准与关键数值
- 服用钙补充剂者斑块体积百分比年化变化最小二乘均值0.09(95%CI -0.20至0.37),未服用者0.01(95%CI -0.27至0.29),组间比较P=0.092。
- 多变量logistic回归模型中,钙补充剂独立与钙化指数年化增加相关(OR 1.15,95%CI 1.05至1.26,P=0.004)。
- 总体年化斑块体积百分比变化均值-0.02±1.9%(P=0.44),钙化指数变化中位数0.02(四分位距0.00至0.06)(P<0.001)。
局限性
- 原文结论指出这些变化对斑块稳定性和心血管结局的影响需进一步研究(requires further investigation)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: This study sought to evaluate and assess the extent of serial coronary artery calcification in response to oral calcium supplementation.
BACKGROUND: Oral calcium supplements are frequently used despite their cardiovascular safety remaining controversial. Their effects on serial coronary calcification are not well established.
METHODS: In a post hoc patient-level analysis of 9 prospective randomized trials using serial coronary intravascular ultrasound, changes in serial percentage of atheroma volume (PAV) and calcium indices (CaI) were compared in matched segments of patients coronary artery disease who were receiving concomitant calcium supplements (n = 447) and in those who did not receive supplements (n = 4,700) during an 18- to 24-month trial period.
RESULTS: Patients (mean age 58 ± 9 years; 73% were men; 43% received concomitant high-intensity statins) demonstrated overall annualized changes in PAV and CaI with a mean of -0.02 ± 1.9% (p = 0.44) and a median of 0.02 (interquartile range: 0.00 to 0.06) (p < 0.001) from baseline, respectively. Following propensity-weighted mixed modeling adjusting for treatment and a range of demographic, clinical, ultrasonic, and laboratory parameters (including but not limited to sex, race, baseline, and annualized change in PAV, baseline CaI, concomitant high-intensity statins, diabetes mellitus, renal function), there were no significant between-group differences in annualized changes in PAV (least-squares mean: 0.09; 95% confidence interval [CI]: -0.20 to 0.37 vs. 0.01; 95% CI: -0.27 to 0.29; p = 0.092) according to calcium supplement intake. Per a multivariable logistic regression model accounting for the range of covariates described, calcium supplementation independently associated with an increase in annualized CaI (odds ratio: 1.15; 95% CI: 1.05 to 1.26; p = 0.004).
CONCLUSIONS: Oral calcium supplementation may increase calcium deposition in the coronary vasculature independent of changes in atheroma volume. The impact of these changes on plaque stability and cardiovascular outcomes requires further investigation.
引用
- Bazarbashi N, Kapadia SR, Nicholls SJ, et al. Oral Calcium Supplements Associate With Serial Coronary Calcification: Insights From Intravascular Ultrasound. JACC Cardiovasc Imaging. 2020. PMID: 32828785. doi:10.1016/j.jcmg.2020.06.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。